First quarter performance driven by strong year-over-year royalty revenue growth of 56%Reaffirms Previously Raised 2026 Full-Year Financial ...

Ligand Pharmaceuticals (NASDAQ:LGND) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from ...

Viking Therapeutics’ collaboration with Ligand Pharmaceuticals has sailed into some trouble, with one of the partners keen to ...

After Xoma Royalty went on a dealmaking spree last year, the biotech royalty aggregator is now itself being bought out by its ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company ...

Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their ...

Orchestra BioMed (Nasdaq:OBIO) announced today that it secured $35 million in total funding through partnerships with Medtronic and Ligand.

Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and ...

By Puyaan Singh April 27 (Reuters) - Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for ...

Ligand Pharmaceuticals has agreed to acquire XOMA Royalty for $39.00 per share of common stock in cash, for a total equity value of approximately $739M. The transaction has been u ...

The all-cash deal adds more than 120 assets to Ligand's portfolio and is expected to close in the third quarter of 2026 ...